• Jaguar Health's Napo Pharmaceuticals reviewed pediatric oral crofelemer findings at an October 30, 2026, gastroenterology conference in Dubai.
• Results showed reduced intravenous nutritional support needs and improved growth in children with microvillus inclusion disease or short bowel syndrome-related intestinal failure.
• Patients treated for more than one year showed no significant clinical or laboratory abnormalities; findings were previously presented in June 2026.
• A randomized, double-blind, placebo-controlled crossover study in microvillus inclusion disease remains underway to support regulatory requirements.
• Napo plans to file a New Drug Application for microvillus inclusion disease in mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611020900ACCESSWRNAPR_____1244889) on November 02, 2026, and is solely responsible for the information contained therein.